{"This": [0, 146], "2022": [1], "European": [2], "Atherosclerosis": [3], "Society": [4], "lipoprotein(a)": [5], "[Lp(a)]": [6], "consensus": [7], "statement": [8, 220], "updates": [9], "evidence": [10, 222], "for": [11, 28, 107, 203, 223, 230, 244], "the": [12, 94, 140], "role": [13], "of": [14, 49, 51, 80, 93, 123, 171, 214, 234], "Lp(a)": [15, 33, 61, 70, 85, 102, 116, 129, 150, 174, 196, 206, 224], "in": [16, 39, 66, 155, 162], "atherosclerotic": [17], "cardiovascular": [18, 64, 193, 209, 231, 245], "disease": [19, 210, 246], "(ASCVD)": [20], "and": [21, 30, 35, 44, 57, 63, 91, 111, 132, 195, 247], "aortic": [22, 95, 248], "valve": [23, 249], "stenosis,": [24], "provides": [25], "clinical": [26, 242], "guidance": [27], "testing": [29, 149, 158], "treating": [31], "elevated": [32, 69], "levels,": [34], "considers": [36], "its": [37], "inclusion": [38], "global": [40, 192], "risk": [41, 73, 105, 122, 184, 194, 215, 228], "estimation.": [42], "Epidemiologic": [43], "genetic": [45], "studies": [46], "involving": [47], "hundreds": [48], "thousands": [50], "individuals": [52], "strongly": [53], "support": [54, 101], "a": [55, 72, 104, 226], "causal": [56, 227], "continuous": [58], "association": [59], "between": [60], "concentration": [62, 151], "outcomes": [65], "different": [67], "ethnicities;": [68], "is": [71, 86, 187, 200], "factor": [74, 106, 185, 229], "even": [75], "at": [76, 152], "very": [77, 204], "low": [78, 115], "levels": [79, 117], "low-density": [81], "lipoprotein": [82], "cholesterol.": [83], "High": [84], "associated": [87], "with": [88, 120, 166, 207], "both": [89], "microcalcification": [90], "macrocalcification": [92], "valve.": [96], "Current": [97], "findings": [98], "do": [99], "not": [100], "as": [103, 225], "venous": [108], "thrombotic": [109], "events": [110], "impaired": [112], "fibrinolysis.": [113], "Very": [114], "may": [118, 136], "associate": [119], "increased": [121], "diabetes": [124], "mellitus": [125], "meriting": [126], "further": [127], "study.": [128], "has": [130, 159], "pro-inflammatory": [131], "pro-atherosclerotic": [133], "properties,": [134], "which": [135], "partly": [137], "relate": [138], "to": [139, 191, 240], "oxidized": [141], "phospholipids": [142], "carried": [143], "by": [144], "Lp(a).": [145], "panel": [147], "recommends": [148], "least": [153], "once": [154], "adults;": [156], "cascade": [157], "potential": [160], "value": [161], "familial": [163], "hypercholesterolaemia,": [164], "or": [165, 168, 175], "family": [167], "personal": [169], "history": [170], "(very)": [172], "high": [173, 205], "premature": [176], "ASCVD.": [177], "Without": [178], "specific": [179, 235], "Lp(a)-lowering": [180, 236], "therapies,": [181], "early": [182], "intensive": [183], "management": [186, 213], "recommended,": [188], "targeted": [189], "according": [190], "level.": [197], "Lipoprotein": [198], "apheresis": [199], "an": [201], "option": [202], "progressive": [208], "despite": [211], "optimal": [212], "factors.": [216], "In": [217], "conclusion,": [218], "this": [219], "reinforces": [221], "outcomes.": [232], "Trials": [233], "treatments": [237], "are": [238], "critical": [239], "confirm": [241], "benefit": [243], "stenosis.": [250]}